← SynDRA
FEDOVAPAGON
SynDRA canonical compound SYN0011677 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AVPR2 |
|---|
| Mechanism of action | vasopressin receptor agonist |
|---|
| Indication | benign prostatic hyperplasia (bph) |
|---|
| Disease area | urology |
|---|
All known targets
Mechanisms of action (all sources)
- vasopressin receptor agonist
- AVPR2 INHIBITOR
Cross-references
Synonyms
- VA-106483
- UNII-VX2GBO4I0V
- VX2GBO4I0V
- CHEMBL518043
- Fedovapagon [INN]
- SCHEMBL2547119
- DTXSID40188331
- MolPort-042-665-819
- BDBM50246575
- ZINC38471398
- DB11734
- NCGC00386702-01
- 1,2-Pyrrolidinedicarboxamide, N2,N2-dimethyl-N1-((2-methyl-4-((2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)methyl)-, (2S)-
- (2S)-N2,N2-dimethyl-N1-((2-Methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide
- FEDOVAPAGON [WHO-DD]
- fedovapagonum
- RefChem:140068
- DTXCID70110822
- orb1707315
- C27H34N4O3
- XNA88736
- MFCD19443737
- AKOS040741722
- DA-53141
- HY-14887
- MS-28508
- CS-0003613
- NS00072275
- E74592
- T15273
- F847522
Look up FEDOVAPAGON in the interactive SynDRA portal →